BRU •
Healthcare •
Biotechnology •
Quote as of 08/21/2026 17:35
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeBRU
Market Capitalization41,431 mln
Float120 mln
Earnings Date07/30/2026
EPS
11.33
Robust
P / E
19.47
Moderately valued
Piotroski F-Score
9
/ 9
Exceptional
Beneish M-Score
-2.49
Borderline
1-Year Forecast
285
Strong upside
Relative Strength
56
/ 100
Slightly ahead
Business Description
UCB is a Belgium-based medicine company founded in 1925 that focuses on treating neurological and immune system conditions. Its product range covers epilepsy, Parkinson's disease, rheumatoid arthritis, psoriasis, osteoporosis, and several rare disorders, among others. The company sells well-known medicines such as Cimzia, Vimpat, Neupro, and Zyrtec, while also advancing a pipeline of new treatments targeting conditions like Alzheimer's disease, lupus, and certain genetic disorders. In addition to developing and selling its own products, UCB also provides manufacturing services to other companies.
